Clinical trials for medicines: apply for approval in the UK

AI Summary

This guidance details the updated requirements for conducting clinical trials in the United Kingdom under the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended in 2025. These regulations became fully effective on April 28, 2026. Sponsors and investigators are required to obtain joint clinical trial approval from both the Medicines and Healthcare products Regulatory Agency (MHRA) and a research ethics committee. Applications must be submitted through the Integrated Research Application System (IRAS) for parallel review. The standard regulatory timeline includes a 7-day validation check followed by a 30-day review period for a decision. Key requirements for a successful application include a detailed clinical protocol, an Investigator’s Brochure, and an Investigational Medicinal Product (IMP) dossier. These documents must confirm adherence to Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) standards. Common issues that lead to application rejection or invalidation include incomplete safety data, lack of manufacturing authorization, and insufficient justification for trial designs. Sponsors must also ensure that all trials are registered in a public database before the first participant is enrolled or within 90 days of receiving approval. If the MHRA issues an 'approval with conditions,' the sponsor must fulfill those specific requirements by the designated deadline; failure to do so will result in the immediate suspension of the trial. The MHRA will assess compliance with these conditions during subsequent inspections to ensure ongoing regulatory adherence.